These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26935789)

  • 1. Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells.
    Zhou W; Chen X; He K; Xiao J; Duan X; Huang R; Xia Z; He J; Zhang J; Xiang G
    Oncol Rep; 2016 May; 35(5):2535-42. PubMed ID: 26935789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma - cell line findings.
    Sriraksa R; Limpaiboon T
    Asian Pac J Cancer Prev; 2013; 14(4):2503-8. PubMed ID: 23725164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
    Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
    J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro.
    Fan S; Ge Y; Liu J; Liu H; Yan R; Gao T; Fan X; Xiao Z; An G
    J Clin Lab Anal; 2021 Oct; 35(10):e23986. PubMed ID: 34462984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum.
    Brosch G; Ransom R; Lechner T; Walton JD; Loidl P
    Plant Cell; 1995 Nov; 7(11):1941-50. PubMed ID: 8535144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
    Fraveto A; Cardinale V; Bragazzi MC; Giuliante F; De Rose AM; Grazi GL; Napoletano C; Semeraro R; Lustri AM; Costantini D; Nevi L; Di Matteo S; Renzi A; Carpino G; Gaudio E; Alvaro D
    PLoS One; 2015; 10(11):e0142124. PubMed ID: 26571380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.
    Jung DE; Park SB; Kim K; Kim C; Song SY
    Sci Rep; 2017 Sep; 7(1):10921. PubMed ID: 28883618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma.
    Koprowski S; Sokolowski K; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
    J Surg Res; 2015 Oct; 198(2):434-40. PubMed ID: 25890434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of inhibitor-resistant histone deacetylase activity in plant-pathogenic fungi.
    Baidyaroy D; Brosch G; Graessle S; Trojer P; Walton JD
    Eukaryot Cell; 2002 Aug; 1(4):538-47. PubMed ID: 12456002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro.
    Deubzer HE; Ehemann V; Kulozik AE; Westermann F; Savelyeva L; Kopp-Schneider A; Riester D; Schwab M; Witt O
    Cancer Lett; 2008 Jun; 264(1):21-8. PubMed ID: 18262346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
    Yin Y; Zhang M; Dorfman RG; Li Y; Zhao Z; Pan Y; Zhou Q; Huang S; Zhao S; Yao Y; Zou X
    Cell Death Dis; 2017 Jun; 8(6):e2856. PubMed ID: 28569784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
    Baradari V; Höpfner M; Huether A; Schuppan D; Scherübl H
    World J Gastroenterol; 2007 Sep; 13(33):4458-66. PubMed ID: 17724801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells.
    Joung KE; Kim DK; Sheen YY
    Arch Pharm Res; 2004 Jun; 27(6):640-5. PubMed ID: 15283467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
    Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
    Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells.
    Deubzer HE; Ehemann V; Westermann F; Heinrich R; Mechtersheimer G; Kulozik AE; Schwab M; Witt O
    Int J Cancer; 2008 Apr; 122(8):1891-900. PubMed ID: 18074352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
    J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
    Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
    He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T
    Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.